icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
NOVEL NS5A INHIBITOR ACH-2928 PHASE 1 RESULTS IN HEALTHY VOLUNTEERS AND HCV GT-1 PATIENTS
 
 
  Reported by Jules Levin
EASL 2012
 
Authors: Vince B1, Lawitz E2, Searle S3, Marbury T4, Robison H5, Robarge L5, and Olek E5 Affiliations: 1Vince and Associates Clinical Research, Overland Park, KS 2Alamo Medical Research, San Antonio, TX, 3Comprehensive Clinical Development, Tacoma, WA, 4Orlando Clinical Research Center, Orlando, FL, 5Achillion Pharmaceuticals Inc., New Haven, CT
 
CONCLUSIONS
 
- Oral doses of ACH-2928 up to 500 mg appear to be safe and well-tolerated in healthy volunteers
- Pharmacokinetic profiles support 10 mg and 60 mg dosing regimens in HCV infected patients
- The mean maximum HCV RNA viral load decline of 3.68 log10 observed in the ACH-2928 60 mg QD dose group shows a robust antiviral effect and no virologic breakthrough with monotherapy compared to the placebo arm decline of 0.54 log10
- These results supports continued investigation of ACH-2928 in both PegIFN/RBV and DAA combinations

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif